Читать книгу Pathy's Principles and Practice of Geriatric Medicine - Группа авторов - Страница 632

The rationale for the use of pyridoxine in MDS is the potential improvement in ineffective erythropoiesis. Pyridoxine is a non‐toxic cofactor required for haem biosynthesis and is usually given for three months in patients with anaemia from MDS, but responses are rare. There is no clear role for androgens, danazole, or vitamins in the therapy of MDS.